3.4 Dosage Regimens and PTA Results
The final recommended regimes and its PTA for patients with different CYP2C19 genotypes and ALB levels are shown in Table 4. As the results exhibited, 2, 4 and 7 mg/kg administered intravenously or orally twice daily are recommended for patients (EM=0) with ALB levels of 20.0~35.0 g/L, 35.1~ 45.0 g/L and 45.1~55.0 g/L, with the PTA of 77.72%, 77.07%, 67.22%, 80.09%, 79.77% and 70.86% respectively. For patients (EM=1) with ALB levels of 20.0~35.0 g/L,35.1~45.0 g/L and 45.1~55.0 g/L, the regimens of 4, 8 and 12 mg/kg by intravenous or oral administration twice daily are considered appropriate (the PTA attained 82.67%, 79.42%, 76.80%, 83.40%, 81.12% and 79.54% respectively).